Novo Nordisk A/S Sponsored ADR (NVO)
Oral Wegovy Approval Is The Critical 2026 Lifeline Novo Nordisk Needs
Novo Nordisk A/S secured FDA approval for oral Wegovy, marking a pivotal expansion in the obesity treatment market. Oral GLP-1 therapies promise greater accessibility and a potentially larger addressable market compared to injectables. NVO's obesity segment, though less reimbursed than diabetes, is growing rapidly at 41% year over year versus 10% for diabetes.
Bear of the Day: Novo Nordisk (NVO)
Novo Nordisk ( NVO ) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human insulins. Based in Bagsværd, Denmark the company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
Novo Nordisk (NVO) closed at $52.56 in the latest trading session, marking a +1.84% move from the prior day.
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?
NVO secures FDA approval for its first oral obesity pill, Wegovy, giving it a first-to-market edge and raising questions about Lilly's next move.
Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill
Novo Nordisk has finally received FDA approval for the Wegovy pill, aiming to regain ground in the obesity drugs market against Eli Lilly. NVO trades close to a 10-year low forward EBITDA multiple of 10.5x, reflecting deep market pessimism despite recent positive momentum. Intense competition with LLY and pricing pressures persist, but NVO's first-mover advantage in oral obesity drugs could catalyze a much-needed turnaround.
Final Trade: NVO, FCX, BA, CLF
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Dr. Ashish Jha talks Novo Nordisk getting approval for Wegovy pill
Dr. Ashish Jha, Brown School of Public Health, joins 'Closing Bell Overtime' to talk Novo Nordisk getting approval fro a Wegovy pill, sending its stock climbing.
Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly's Looming Pill?
Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk ‘s ( NYSE:NVO ) Wegovy weight-loss pill, the first of its kind.
Could Novo Nordisk's New Weight-Loss Pill Be Just What Its Stock Needs?
Could a new weight-loss pill be just what Novo Nordisk (NVO) needs to revive its stock?
Novo Nordisk's Christmas Gift To Shareholders: The Wegovy Pill Has Been Approved
Novo Nordisk A/S secured FDA approval for the oral Wegovy pill, marking a pivotal catalyst for a 2026 turnaround. The Wegovy pill delivers 16.6% weight loss in 64 weeks, outpacing Eli Lilly's Orforglipron and offering long-term cardiovascular benefits. NVO will enjoy at least 90 days of U.S. market exclusivity, with robust early demand expected due to oral preference and competitive pricing at $149/month.
Explainer: What Novo Nordisk's weight-loss pill approval means for company, patients
The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could potentially expand access to millions of patients and give the Danish company a much-needed fillip in the red-hot market.
Novo Nordisk surges as US approves first weight-loss pill
Novo Nordisk (NYSE:NVO) shares rose nearly 8% after the US Food and Drug Administration approved its Wegovy pill, the first oral GLP-1 treatment for weight management. Currently, GLP-1 treatments for weight-loss and diabetes are given by injection, with Denmark-based Novo first to market with its Wegovy and Ozempic drugs, before being overtaken by Eli Lilly, whose injectable Mounjaro and Zepbound control around 58% of total prescriptions versus Novo's 42%.
